volume 2, issue 8, PS470 2007
DOI: 10.1097/01.jto.0000283418.42111.77
View full text
|
|
Share

Abstract: Background: Sunitinib malate is an oral, multitargeted tyrosine kinase inhibitor of VEGFRs, PDGFRs, KIT, RET, and FLT3. In a multicenter phase II trial of sunitinib administered on a 4/2 schedule (4 weeks on treatment followed by 2 weeks off) in recurrent advanced NSCLC, 11% of patients achieved a partial response (PR; Socinski, ESMO 2006). We report results from a planned extension of this phase II study, which investigated the efficacy and safety of sunitinib given on a continuous dosing schedule. Methods: P…

Expand abstract

Search citation statements

Order By: Relevance

Citation Types

0
0
0

Paper Sections

0
0
0
0
0

Publication Types

0
0
0
0

Relationship

0
0

Authors

Journals